Chief Medical Officer
A respected clinician and seasoned medical executive with more than two decades of experience in the field of oncology, Dr. Song oversees Cynvenio’s translational and clinical research programs.
Dr. Song was formerly a member of the faculty at Cedars Sinai Medical Center, in the Samuel Oschin Cancer Center department of radiation oncology and biomedical sciences. In addition, he serves as Chief Medical Officer at AT-Gen Co. Ltd, where he oversees all clinical aspects of the company’s NK Vue, an ELISA-based blood test which measures natural killer cell activity. Previously, Dr. Song served as Chief Medical Officer at Berg Health, where he navigated the company through its launch of several phase I trials.
Dr. Song graduated with honors from the University of Chicago and received his M.D. degree from George Washington University. He completed his residency in radiation oncology at the University of Chicago Medical Center and a brachytherapy fellowship at the Institut Gustave Roussy. Dr. Song was also awarded an ASTRO Research Fellowship award by the American Society for Radiation Oncology for his work on radiation induced gene therapy.